Riboxin - instructions for use. Pharmacological action and correct dosage of Riboxin Method of using Riboxin in ampoules

Riboxin: instructions for use and reviews

Latin name: Riboxin

ATX code: C01EB

Active substance: Inosine

Manufacturer: Binnopharm ZAO (Russia); Asfarma (Russia); Ozon LLC (Russia); Irbit Chemical Pharmaceutical Plant (Russia); Borisov Medical Preparations Plant (Republic of Belarus)

Updating the description and photo: 13.08.2019

Riboxin is a drug that regulates metabolic processes and has an antihypoxic and antiarrhythmic effect.

Release form and composition

• Film-coated tablets: round, biconvex, yellow; tablet core - white or almost white (in a blister pack of 10 pcs., in a cardboard pack 1-5 or 10 packs; in a blister pack 25 pcs., in a cardboard pack 1-5 or 10 packs; 50 pcs each . in a polymer jar, 1 jar in a cardboard pack; 50 pieces in a dark glass jar, 1 jar in a cardboard pack);
• Film-coated tablets: biconvex, from yellow-orange to light yellow in color, when cut, two layers are visible (in a blister pack of 10 pcs., in a cardboard pack 1, 2, 3, 4 or 5 packs);
• Solution for intravenous (i.v.) administration: colorless or slightly colored transparent liquid (5 and 10 ml each in glass ampoules of neutral color: 10 ampoules in a cardboard pack; 5 or 10 pcs. in a blister pack, 1 or 1 in a cardboard pack 2 packs);
• Capsules: No. 1, gelatin, solid structure, red, inside the capsules there is white powder (10 pcs in a blister pack, 5 packs in a cardboard box).

1 film-coated tablet contains:

• Active ingredient: inosine (riboxin) – 0.2 g;
• Auxiliary components: lactose monohydrate, microcrystalline cellulose, copovidone, calcium stearate;
• Shell composition: Opadry II (series 85) (macrogol-3350, partially hydrolyzed polyvinyl alcohol, titanium dioxide (E171), aluminum varnish based on sunset yellow dye (E110), aluminum varnish based on indigo carmine (E132), aluminum varnish based on quinoline yellow dye (E104), talc).

1 film-coated tablet contains:

• Auxiliary components: sugar, potato starch, titanium dioxide, water-soluble methylcellulose, Tween-80, tropeolin O, stearic acid.

1 ml of solution for intravenous administration contains:

• Active ingredient: inosine – 0.02 g;
• Auxiliary components: hexamethylenetetramine (methenamine), 1M sodium hydroxide solution, water for injection.

1 capsule contains:

• Active ingredient: inosine – 0.2 g;
• Auxiliary components: potato starch, calcium stearate;
• Shell composition: pharmaceutical gelatin, methyl parahydroxybenzoate, glycerol, propyl parahydroxybenzoate, titanium dioxide, Charming Red dye (E129), sodium lauryl sulfate, purified water.

Pharmacological properties

Pharmacodynamics

Riboxin is a drug that regulates metabolic processes. It belongs to the category of purine derivatives (nucleosides) and is a precursor to adenosine triphosphate (ATP). Riboxin is characterized by antiarrhythmic, metabolic and antihypoxic effects. It normalizes the energy balance of the myocardium, stabilizes coronary circulation, and eliminates the consequences of renal intraoperative ischemia.

This substance is directly involved in glucose metabolism and activates metabolism in the absence of ATP and under hypoxic conditions. Riboxin accelerates the metabolism of pyruvic acid, which helps normalize the process of tissue respiration, and also ensures the activation of xanthine dehydrogenase. The drug stimulates the production of nucleotides and increases the activity of certain enzymes of the Krebs cycle. Riboxin penetrates cells, improving energy metabolism and having a positive effect on metabolic processes in the myocardium: the compound increases the strength of heart contractions and ensures more complete relaxation of the myocardium in diastole. As a result, the stroke volume of blood increases. Riboxin inhibits platelet aggregation and improves tissue regeneration (mainly the gastrointestinal mucosa and myocardium).

Pharmacokinetics

Riboxin is well absorbed from the gastrointestinal tract and metabolized in the liver, forming glucuronic acid, which is subsequently subject to oxidation. The compound is excreted in small quantities through the kidneys.

Indications for use

According to the instructions, Riboxin is used as part of complex therapy:

• The period after myocardial infarction;
• Cardiac ischemia;
• Heart rhythm disturbances due to the use of cardiac glycosides;
• Myocardial dystrophy;
• Liver diseases: fatty degeneration, hepatitis, cirrhosis;
• Urocoproporphyria.

In addition, a solution for intravenous administration is prescribed during surgery on an isolated kidney for pharmacological protection when the blood circulation is turned off.

Contraindications

• Age up to 18 years;
• Gout;
• Hyperuricemia;
• The period of pregnancy and breastfeeding;
• Individual intolerance to the components of the drug.

In addition, the use of film-coated tablets is contraindicated in patients with lactase deficiency, lactose intolerance, or glucose-galactose malabsorption.

Instructions for use of Riboxin: method and dosage

Film-coated tablets and film-coated tablets

Riboxin tablets are taken orally before meals.

Recommended dosage regimen: at the beginning of therapy - 0.2 g 3-4 times a day, after 2-3 days of treatment (if the drug is adequately tolerated) the patient is transferred to taking 0.4 g 3 times a day. To achieve a therapeutic effect, a gradual increase in the dose is possible, but not more than 2.4 g per day. Course duration is 30-90 days.

For the treatment of urocoproporphyria, 0.2 g is prescribed 4 times a day for 30-90 days.

Solution for intravenous administration

Riboxin solution is administered slowly intravenously in a stream or drip. The infusion rate should not exceed 40-60 drops per minute.

To prepare an infusion solution, it is necessary to mix the drug solution with 250 ml of 0.9% sodium chloride solution or 5% glucose solution.

Recommended dosage for intravenous drip administration: initial dose – 0.2 g (10 ml) 1 time per day. If there is a good response to the drug, the dose can be increased to 0.4 g (20 ml) 1-2 times a day. The course of treatment is 10-15 days.

Dosing regimen for jet administration:

• Acute cardiac arrhythmias: single administration in a dose of 0.2-0.4 g (10-20 ml of solution);
• Pharmacological protection of the kidneys: a single administration 5-15 minutes before turning off the blood circulation - 1.2 g (60 ml), then immediately after restoration of the hepatic artery - 0.8 g (40 ml).

Capsules

Capsules are intended to be taken orally before meals.

Recommended dosage: initial dose – 1 pc. 3-4 times a day, with adequate tolerability of the drug for 2-3 days of therapy to achieve the desired effect, the dose can be increased to 2 pcs. 3 times a day (1.2 g). The daily dose should not exceed 12 pcs. (2.4 g).

For urocoproporphyria, the patient is prescribed 1 pc. 4 times a day.

Duration of treatment is 30-90 days.

Side effects

• Allergic reactions: possible – skin hyperemia, skin itching;
• Other: rarely - increased levels of uric acid in the blood; during long-term therapy - exacerbation of gout.

In addition, the use of Riboxin capsules and tablets can cause an allergic reaction in the form of urticaria.

Overdose

When Riboxin is administered in high doses, the patient may experience increased individual sensitivity reactions to the drug. In this case, the drug is discontinued and desensitizing therapy is prescribed. Sometimes there is an increase in the concentration of uric acid in the blood, causing an exacerbation of the condition in patients with gout and requiring discontinuation of Riboxin.

special instructions

It is not recommended to prescribe Riboxin for emergency assistance in case of cardiac dysfunction.

If skin hyperemia occurs, immediate discontinuation of the drug is required.

The use of the drug should be accompanied by regular monitoring of the level of uric acid concentration in urine and blood.

Does not affect the patient's ability to drive vehicles and machinery.

Drug interactions

The action of inosine as part of complex therapy increases the effectiveness of antianginal, antiarrhythmic, and inotropic drugs.

Concomitant use of immunosuppressants (including antithymocyte immunoglobulin, gamma-D-glutamyl-D-tryptophan, cyclosporine) reduces the effectiveness of inosine.

No other clinically significant interactions with Riboxin have been established.

Analogs

Analogues of Riboxin are: Inosie-F, Inosine, Inosine-Eskom, Riboxin Bufus, Riboxin-Vial, Riboxin-LekT, Riboxin-Ferein, Ribonosine.

Terms and conditions of storage

Keep out of the reach of children and protected from light at temperatures up to 25 °C; protect tablets and capsules from moisture.

Shelf life: tablets and solution – 3 years, capsules – 2 years.

In this article you can read the instructions for use of the drug Riboxin. Reviews of site visitors - consumers of this medicine, as well as the opinions of specialist doctors on the use of Riboxin in their practice are presented. We kindly ask you to actively add your reviews about the drug: whether the medicine helped or did not help get rid of the disease, what complications and side effects were observed, perhaps not stated by the manufacturer in the annotation. Riboxin analogues in the presence of existing structural analogues. Use for the treatment of myocardial infarction, hepatitis and other metabolic diseases in adults, children, as well as during pregnancy and lactation.

Riboxin- belongs to the group of drugs that regulate metabolic processes. The drug is a precursor for the synthesis of purine nucleotides: adenosine triphosphate and guanosine triphosphate. The active ingredient of the drug is Inosine.

It has antihypoxic, metabolic and antiarrhythmic effects. Increases the energy balance of the myocardium, improves coronary circulation, and prevents the consequences of intraoperative renal ischemia. It is directly involved in glucose metabolism and promotes the activation of metabolism under conditions of hypoxia and in the absence of adenosine triphosphate.

Activates the metabolism of pyruvic acid to ensure the normal process of tissue respiration, and also promotes the activation of xanthine dehydrogenase. Stimulates the synthesis of nucleotides, enhances the activity of some Krebs cycle enzymes. Penetrating into cells, it increases the energy level, has a positive effect on metabolic processes in the myocardium, increases the strength of heart contractions and promotes more complete relaxation of the myocardium in diastole, resulting in an increase in stroke volume of blood.

Reduces platelet aggregation, activates tissue regeneration (especially the myocardium and the mucous membrane of the gastrointestinal tract.

Pharmacokinetics

Well absorbed in the gastrointestinal tract. Metabolized in the liver with the formation of glucuronic acid and its subsequent oxidation. A small amount is excreted by the kidneys.

Indications

• myocardial dystrophy;
• condition after myocardial infarction;
• congenital and acquired heart defects;
• heart rhythm disturbances, especially with glycoside intoxication;
• myocarditis;
• dystrophic changes in the myocardium after heavy physical exertion and infectious diseases or due to endocrine disorders;
• hepatitis;
• cirrhosis of the liver;
• fatty liver, incl. caused by alcohol or drugs;
• prevention of leukopenia during radiation exposure;
• operations on an isolated kidney (as a means of pharmacological protection in the event of a temporary lack of blood circulation in the operated organ).

Release forms

Film-coated tablets 200 mg.

Capsules 200 mg.

Solution for intravenous administration (injections in injection ampoules) 20 mg/ml.

Instructions for use and dosage regimen

Tablets, capsules

Prescribed for adults orally, before meals.

The daily dose when taken orally is 0.6-2.4 g. In the first days of treatment, the daily dose is 0.6-0.8 g (200 mg 3-4 times a day). If well tolerated, the dose is increased (on days 2-3) to 1.2 g (0.4 g 3 times a day), if necessary - to 2.4 g per day.

Course duration is from 4 weeks to 1.5-3 months.

For urocoproporphyria, the daily dose is 0.8 g (200 mg 4 times a day). The drug is taken daily for 1-3 months.

Ampoules

When taken orally, the initial daily dose is 600-800 mg, then the dose is gradually increased to 2.4 g per day in 3-4 doses.

When administered intravenously (stream or drip in the form of a dropper) the initial dose is 200 mg 1 time per day, then the dose is increased to 400 mg 1-2 times per day.

The duration of the course of treatment is determined individually.

Side effect

• allergic reactions in the form of urticaria, skin itching, skin hyperemia (discontinuation of the drug is required);
• increased concentration of uric acid in the blood and exacerbation of gout (with long-term use).

Contraindications

• hypersensitivity to the drug;
• gout;
• hyperuricemia;
• children under 3 years of age;
• fructose intolerance and glucose/galactose malabsorption syndrome or sucrase/isomaltase deficiency.

Use during pregnancy and breastfeeding

The safety of using the drug Riboxin during pregnancy and lactation has not been established. The use of Riboxin is contraindicated during pregnancy. During treatment with Riboxin, breastfeeding should be stopped.

Use in children

Contraindicated in children under 3 years of age.

special instructions

During treatment with Riboxin, the concentration of uric acid in the blood and urine should be monitored.

Information for patients with diabetes: 1 tablet of the drug corresponds to 0.00641 bread units.

Does not affect the ability to drive vehicles and control mechanisms that require increased concentration.

Drug interactions

Immunosuppressants (azathioprine, antilympholine, cyclosporine, thymodepressin, etc.) when used simultaneously reduce the effectiveness of Riboxin.

Analogues of the drug Riboxin

Structural analogues of the active substance:

• Inozie-F;
• Inosine;
• Inosin-Eskom;
• Riboxin Bufus;
• Riboxin-Vial;
• Riboxin-LecT;
• Riboxin-Ferein;
• Riboxin solution for injection 2%;
• Ribonosine.

If there are no analogues of the drug for the active substance, you can follow the links below to the diseases for which the corresponding drug helps, and look at the available analogues for the therapeutic effect.

1 ml of solution contains

active substance: inosine - 20 mg;

excipients: hexamethylenetetramine, 1 M sodium hydroxide solution, water for injection.

Description

Transparent colorless liquid

Pharmacotherapeutic group

Other cardiotonic drugs.

ATS code C01EV

Pharmacological properties

Pharmacokinetics

When administered intravenously, riboxin is quickly distributed in tissues, metabolized in the liver, where it is completely utilized in the biochemical reactions of the body. Excreted mainly in urine.

Pharmacodynamics

Riboxin is a metabolic drug that has antihypoxic and antiarrhythmic effects. It is a precursor of ATP, is directly involved in glucose metabolism and promotes metabolism activation under hypoxic conditions and in the absence of ATP. The drug activates the metabolism of pyruvic acid to ensure the normal process of tissue respiration and promotes the activation of xanthine dehydrogenase.

Riboxin has a positive effect on metabolism in the myocardium, in particular, it increases the energy balance of cells, stimulates the synthesis of nucleotides, and increases the activity of a number of Krebs cycle enzymes. The drug normalizes the contractile activity of the myocardium and promotes complete relaxation of the myocardium in diastole due to the ability to bind calcium ions that penetrated the cells during their excitation, and activates tissue regeneration (especially the myocardium and the mucous membrane of the digestive canal).

Use in pediatrics

Children under 12 years of age are prescribed depending on weight, at the rate of 10-20 mg/kg body weight (divided into 2-3 doses).

The duration of treatment is determined by the attending physician

Indications for use

Coronary heart disease, incl. myocardial infarction, angina pectoris, coronary insufficiency (as part of complex therapy)

Heart rhythm disturbances

Intoxication with cardiac glycoside drugs

Treatment of cardiomyopathies of various origins, myocardial dystrophies (due to heavy physical exertion, infectious and endocrine origins), myocarditis

Liver diseases (hepatitis, liver cirrhosis, fatty liver)

To improve visual function in open-angle glaucoma with normalized intraocular pressure.

Directions for use and doses

Adults and children over 12 years of age are prescribed intravenously by drip or stream. First, 200 mg (10 ml of 2% solution) is administered once a day, then, if well tolerated, up to 400 mg (20 ml of 2% solution) 1-2 times a day. The course of treatment is determined individually (on average 10-15 days). When administered drip into a vein, a 2% solution of the drug is diluted in a 5% glucose solution or 0.9% sodium chloride solution (up to 250 ml). The drug is administered drip-wise slowly, 40-60 drops per minute. In case of acute cardiac arrhythmias, jet injection in a single dose of 200 - 400 mg (10-20 ml of 2% solution) is possible.

Side effects

Arterial hypotension, tachycardia, general weakness

Hyperemia and itching of the skin

Allergic reactions (urticaria, angioedema, fever, shortness of breath)

Lipodystrophy

In rare cases, during treatment, an increase in the level of uric acid in the blood may occur, and with prolonged treatment, an exacerbation of gout may occur.

Contraindications

Increased individual sensitivity to the drug

Gout

Hyperuricemia

The restriction to taking Riboxin is renal failure

Drug interactions

When used as part of complex therapy, Riboxin helps to increase the effectiveness of antiarrhythmic, antianginal and inotropic drugs.

With simultaneous use of Riboxin with beta-blockers, the effect of Riboxin does not decrease. In combination with cardiac glycosides, the drug can prevent the occurrence of arrhythmias and enhance the inotropic effect.

When used simultaneously with immunosuppressants, the effectiveness is reduced.

Clinically significant interactions of Riboxin with drugs from other groups have not been described.

Riboxin should not be mixed in the same syringe with other medications to avoid chemical incompatibility of the drugs.

special instructions

In case of renal failure, the use of the drug is possible only when, in the opinion of the doctor, the expected positive effect exceeds the possible risk of use.

During treatment, the level of uric acid in the blood should be regularly monitored.

Prescribe the drug with caution in case of impaired renal function.

If itching and hyperemia of the skin occurs, the drug should be discontinued.

Use in pediatrics

In children over 12 years of age, it is prescribed taking into account the benefit/risk ratio.

Pregnancy and lactation

During pregnancy and lactation, Riboxin is prescribed taking into account the benefit/risk ratio

Features of the effect of the drug on the ability to drive a vehicle or potentially dangerous mechanisms

Care should be taken when driving vehicles and potentially hazardous activities that require increased concentration.

Riboxin is a drug that regulates metabolic processes in the myocardium, reduces tissue hypoxia, and improves coronary circulation.

It has antihypoxic, metabolic and antiarrhythmic effects. Increases the energy balance of the myocardium, improves coronary circulation, and prevents the consequences of intraoperative renal ischemia.

It is directly involved in glucose metabolism and promotes the activation of metabolism under conditions of hypoxia and in the absence of adenosine triphosphate.

Clinical and pharmacological group

A drug that normalizes myocardial metabolism and reduces tissue hypoxia.

Terms of sale from pharmacies

Can be bought without a doctor's prescription.

Price

How much does Riboxin cost in pharmacies? The average price is 60 rubles.

Composition and release form

Traditionally, the drug is produced in the form factor of tablets, which are coated with a special film coating. The color of the tablets varies from yellowish to yellow-orange. The tablets are biconvex, round, slightly rough; when cut, it is clear that the core is white.

• The main substance of the drug is inosine. There are also excipients including stearic acid, methylcellulose, potato starch and sucrose. The shell also contains yellow Opadry II.

An alternative form of release is capsules with a 2% solution, which are used when injections of this drug are given.

pharmachologic effect

Inosine, which is the active ingredient of Riboxin, helps regulate metabolic processes. The drug has antihypoxic and antiarrhythmic effects. It is able to accelerate metabolic processes in the myocardium and positively influence metabolic processes in the heart muscle. In addition, it helps to adequately relax the heart muscle during diastole.

The active ingredient Riboxin takes part in glucose metabolism and helps restore ischemic tissue, and also stimulates the normalization of blood circulation in the coronary vessels. Treatment with this drug helps reduce tissue hypoxia and activate all metabolic processes in the myocardium.

Indications for use

Lkx is it prescribed? The patient has to use Riboxin prescribed by the doctor, with different dosages, for many reasons:

1. Prolonged excessive physical activity, which negatively affects the body as a whole;
2. Riboxin is in demand in sports, to support professional athletes during long-term training;
3. Indications for use are for the diagnosis of uroporphyria (metabolic functions are impaired);
4. Complements the main composition of medications for open-angle therapy;
5. Riboxin is indicated for oncology, during radiation therapy, which helps to facilitate the perception of the procedure and reduce the adverse response to its implementation;
6. In the complex treatment of IHD (coronary artery disease). Starting to take a medicinal drug is possible regardless of the phase of the disease, and during the recovery period following the incident;
7. Myocardium and cardiomyopathy initiate indications for long-term use of Riboxin;
8. When the heartbeat rhythm is normalized (). The best effect is achieved in the treatment of pathology caused by an overdose of certain drugs;
9. Complex drug therapy for liver pathology: fatty degeneration, manifestation of toxic disorders in liver cells (a consequence of taking medications, complications when performing professional duties);
10. Riboxin is prescribed during pregnancy at the discretion of the attending physician.

Contraindications

• hyperuricemia;
• gout;
• glucose/galactose malabsorption syndrome, fructose intolerance or isomaltase/sucrase deficiency (for film-coated tablets);
• age under 18 years;
• period of pregnancy and breastfeeding;
• hypersensitivity to the substances contained in the drug.

Caution when prescribing Riboxin should be observed in the presence of the following diseases/conditions:

• renal failure;
• diabetes mellitus (for film-coated tablets).

Prescription during pregnancy and lactation

Riboxin is prescribed to many women during pregnancy. Many patients are frightened by the fact that in the instructions for the drug one can often find information that the medicine is contraindicated for pregnant women. However, you should not be afraid of this, since the contraindication is based on the fact that clinical studies in this area have not yet been conducted. And this despite the fact that today there is quite a lot of experience with the successful use of Riboxin during pregnancy. The medicine does not have a pathological effect on either the fetus or its mother, so there is no reason for concern. The only contraindication here may be individual intolerance to the drug or its components.

Riboxin is an antihypoxant, an antioxidant, and a good means of improving metabolic processes in tissues, which is especially important during the period of bearing a child.

The drug is prescribed to prevent heart disease and support cardiac activity during periods of increased stress. Riboxin is often administered directly during childbirth, since the load on the heart at such a moment is especially high.

Doctors often prescribe the medicine if a pregnant woman has gastritis and liver disease in order to treat existing problems. The drug helps normalize gastric secretion and reduce unpleasant symptoms.

A doctor may prescribe Riboxin during pregnancy if fetal hypoxia is detected. By normalizing metabolic processes in tissues, the medicine reduces the degree of oxygen starvation of the fetus.

If the drug is well tolerated, expectant mothers take 1 tablet orally 3-4 times a day for 1 month. Despite the harmlessness of the medicine, as in any other case, Riboxin should be prescribed by a doctor strictly on an individual basis.

Dosage and method of administration

As indicated in the instructions for use, Riboxin is prescribed to adults orally, before meals.

1. The daily dose when taken orally is 0.6-2.4 g. In the first days of treatment, the daily dose is 0.6-0.8 g (200 mg 3-4 times a day). If well tolerated, the dose is increased (on days 2-3) to 1.2 g (0.4 g 3 times a day), if necessary - to 2.4 g per day.
2. Course duration is from 4 weeks to 1.5-3 months.

For urocoproporphyria, the daily dose is 0.8 g (200 mg 4 times a day). The drug is taken daily for 1-3 months.

Injection solution

Methods of administering Riboxin: intravenously in a slow stream or drip (40-60 drops in 1 minute).

The initial dose is 10 ml of solution (200 mg of inosine) once a day; if the therapy is well tolerated by the patient, the single dose is increased by 2 times with a frequency of use of 1-2 times a day. The duration of use of the drug is 10-15 days.

Injection of Riboxin is possible for acute cardiac arrhythmias, a single dose is from 10 to 20 ml.

For the purpose of pharmacological protection of kidneys subjected to ischemia, the drug is administered intravenously in a stream: 60 ml during 5-15 minutes of turning off the circulation by clamping the renal artery, and then another 40 ml immediately after blood circulation is restored.

For drip administration, the Riboxin solution must be diluted to a volume of 250 ml (5% glucose solution (dextrose) or 0.9% sodium chloride solution).

Side effect

Side effects are possible, so after the first dose of the drug you need to carefully monitor the patient's condition. Riboxin may cause the following undesirable reactions:

1. Headache, nausea, vomiting.
2. Exacerbation of gout, hyperuricemia.
3. General weakness.
4. Allergic reactions (including immediate type).
5. Rash, itching, skin changes.
6. Increased heart rate and drop in blood pressure.
7. Dizziness, increased sweating.
8. Discomfort at the injection site.

If side effects occur, the drug is discontinued.

Overdose

Currently, cases of overdose with Riboxin tablets have not been established.

special instructions

During treatment with Riboxin, the concentration of uric acid in the blood and urine should be monitored.

Information for patients with diabetes: 1 tablet of the drug corresponds to 0.00641 bread units.

Does not affect the ability to drive vehicles and control mechanisms that require increased concentration.

Interaction with other drugs

Pharmacological interactions mainly occur with drugs of other cardiac groups. Riboxin can enhance the effect of heparin, since it itself affects platelet aggregation.

It also enhances the inotropic effect of cardiac glycosides and prevents the occurrence of arrhythmias.

When taken simultaneously with beta-blocker medications, the effect of Riboxin does not change. It is also allowed to combine it with nitroglycerin, spironolactone, nifedipine, furosemide.

The solution is not compatible in the same container with pyridoxine, heavy metal salts, alkaloids, and acids. Riboxin cannot be mixed with solvents other than those recommended.